Citadel Advisors - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 194 filers reported holding SAGE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$11,639,389
-18.7%
565,568
+85.8%
0.00%0.0%
Q2 2023$14,309,409
+236.2%
304,326
+200.1%
0.00%
+100.0%
Q1 2023$4,255,751
-26.3%
101,424
-33.0%
0.00%0.0%
Q4 2022$5,776,875
-45.1%
151,465
-43.6%
0.00%
-50.0%
Q3 2022$10,523,000
+116.9%
268,696
+78.9%
0.00%
Q2 2022$4,851,000
-47.3%
150,190
-46.0%
0.00%
-100.0%
Q1 2022$9,206,000
-83.2%
278,146
-78.4%
0.00%
-75.0%
Q4 2021$54,835,000
+31.4%
1,289,045
+36.9%
0.01%
+50.0%
Q3 2021$41,727,000
-34.9%
941,690
-16.6%
0.01%
-42.9%
Q2 2021$64,117,000
+211.1%
1,128,610
+309.9%
0.01%
+133.3%
Q1 2021$20,608,000
-64.2%
275,319
-58.6%
0.01%
-60.0%
Q4 2020$57,489,000
-42.0%
664,544
-59.1%
0.02%
-46.4%
Q3 2020$99,189,000
+25.4%
1,622,863
-14.7%
0.03%0.0%
Q2 2020$79,069,000
+269.0%
1,901,613
+154.9%
0.03%
+180.0%
Q1 2020$21,428,000
-67.0%
746,107
-17.1%
0.01%
-65.5%
Q4 2019$64,988,000
+20.2%
900,222
+133.6%
0.03%
+11.5%
Q3 2019$54,053,000
+26.3%
385,297
+64.9%
0.03%
+36.8%
Q2 2019$42,792,000
+98.9%
233,723
+72.8%
0.02%
+90.0%
Q1 2019$21,518,000
-13.1%
135,287
-47.6%
0.01%
-28.6%
Q4 2018$24,754,000
-40.0%
258,417
-11.6%
0.01%
-22.2%
Q3 2018$41,291,000
+148.0%
292,322
+174.8%
0.02%
+125.0%
Q2 2018$16,649,000
-17.4%
106,361
-15.0%
0.01%
-27.3%
Q1 2018$20,156,000
-12.8%
125,146
-10.8%
0.01%
-26.7%
Q4 2017$23,117,000
+108.0%
140,351
-21.3%
0.02%
+66.7%
Q3 2017$11,114,000
+75.3%
178,400
+124.1%
0.01%
+80.0%
Q2 2017$6,341,000
-43.9%
79,611
-49.9%
0.01%
-54.5%
Q1 2017$11,302,000
+102.9%
159,032
+45.8%
0.01%
+83.3%
Q4 2016$5,569,000
-90.8%
109,060
-91.7%
0.01%
-90.2%
Q3 2016$60,312,000
+207.9%
1,309,713
+101.5%
0.06%
+177.3%
Q2 2016$19,585,000
+25.8%
650,008
+33.9%
0.02%
+10.0%
Q1 2016$15,565,000
+11.4%
485,511
+102.6%
0.02%
+33.3%
Q4 2015$13,973,000
+158.9%
239,673
+87.9%
0.02%
+200.0%
Q3 2015$5,398,000
+722.9%
127,546
+877.1%
0.01%
+400.0%
Q1 2015$656,000
-67.1%
13,054
-76.0%
0.00%
-50.0%
Q4 2014$1,993,000
+54.1%
54,462
+32.7%
0.00%
+100.0%
Q3 2014$1,293,00041,0370.00%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
RTW INVESTMENTS, LP 5,149,482$105,976,3402.24%
Palo Alto Investors LP 1,005,776$20,698,8701.96%
Boxer Capital, LLC 1,094,000$22,514,5201.20%
Bellevue Group AG 3,513,351$72,304,7641.16%
PDT Partners, LLC 181,625$3,737,8430.47%
EASTERLY INVESTMENT PARTNERS LLC 195,643$4,026,3330.44%
Harvest Investment Services, LLC 30,302$623,6150.40%
Simplify Asset Management Inc. 120,030$2,470,2170.28%
SAMLYN CAPITAL, LLC 739,867$15,226,4630.25%
CAXTON ASSOCIATES LP 68,035$1,400,1600.19%
View complete list of SAGE THERAPEUTICS INC shareholders